I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Monday, March 25, 2019

Drug Resistance in Metastatic Triple Negative Breast Cancer Research 2019

In August of 2017, Mary Westphal, Executive Director of Komen of Northwest Ohio connected me with Dr. Amit Tiwari, Assistant Professor of University of Toledo Department of Pharmacology and Experimental Therapeutics.  Dr. Tiwari contacted me in regards to a research project that he has been researching for a few years on Drug Resistance in Metastatic Triple Negative Breast Cancer.  I immediately was eager to learn more on his research since this was the type of breast cancer I was diagnosed with in 2009.  I agreed to meet up with Dr. Tiwari and his assistant researcher, Angelique for lunch where he presented to me his research, overcoming drug resistance in Triple Negative Breast Cancer cells in a culture dish setting.  
Dr. Tiwari was ready to continue his research, moving on to testing in mice models and ultimately to human clinical trials but needed additional financial support and was in the process of applying for a Komen national grant that would further his research.   A part of the stipulation of the Komen grant was that his research would have to have a Patient Advocate Mentor on his team and asked me if I was interested in taking on this role, as I have been very active in the Triple Negative Breast Cancer community.  Without hesitation I asked,  "where do I sign?"  I was so honored to be asked to be a part of his research team and immediately started working on my bio-sketch of my involvement in breast cancer events,  awareness, conferences, volunteering, fundraising and public speaking over the years since my diagnosis in 2009.  In September 2017, Dr. Tiwari submitted his grant application along with his 120+ pages of his research proposal that included my bio-sketch for review to Komen National Headquarters and then we wait for the response...  

In the meantime, Dr. Tiwari and I have met several times discussing his research, my role as his Patient Advocate Mentor and introduced to me members of his research team at The University of Toledo Department of Pharmacology and Experimental Therapeutics and gave me a tour of his research lab.  Also, I had the opportunity to view live Triple Negative Breast Cancer cells under the microscope that appeared to be forming clusters.  

Almost a year later in September 2018, Dr. Tiwari notified me that he was awarded nearly $450,00.00 to continue his research on Drug Resistance in Metastatic Triple Negative Breast Cancer... and had recently discovered a molecule that reverses the drug resistance and making it more responsive to treatment.  I am just ecstatic that there is a potential cure for Triple Negative Breast Cancer and that this research is happening in my own back yard so to speak!  I have been longing for TNBC research in Toledo ever since I was diagnosed and no effective targeted therapy has been yet to be discovered.  I want to commit myself to this project and be involved in as much as possible to expand my understanding of how this research progresses and continue to learn as much as I can to better assist Dr. Tiwari, his team and our local breast cancer community.

Recently, I have attended a lab meeting learning about the different experiments that they are studying.  Also, I sat in and observe an experiment on bone marrow cells performed by Dr. Diwakar Tukaramrao.  My observation of the experiment was very interesting in seeing  firsthand how testings are prepared and the amount of preparation is done before the actual testing is performed.  I learned about how cells must be kept at 37 in freezers, refrigerators, incubators and be kept on ice when transporting.  I learned that some cells are light sensitive and are stored in amber colored glass bottles, and the lights in the testing sterile area needs to be turned off during testing exposure.  Also, I assisted in the lab with preparation by putting testing tubes in its multiple storage racks that were needed by another researcher, Mohammed.

I have always said my fight is not over until all my TNBC sisters are safe.
Stay tuned to my blog with updates of progress and my participation in this TNBC study. Truly, Melissa

Melissa looking at live Triple Negative Breast 
Cancer cells under the microscope

Melissa looking at colon cancer 
cells in the research lab

Melissa and Dr. Amit Tiwari


Assisting Kyle with keeping
research cells on ice to reduce
apoptosis 


Live cells handled from 
37℃ freezer to ice


Observing a research experiment
with Dr. Diwari Tukaramrao
and Kyle

Angelique presenting her studies on
Triple Negative Breast Cancer cells


Friday, March 22, 2019

Panel Discussion on Medical Updates on Breast Cancer Treatments 2018

On October 25, 2018, I attended a program at University of Toledo Dana Cancer Center on Individualized Breast Cancer Treatments with their professors and medical team.
A lot of advancement in breast-conserving surgeries that are currently being used in treatments. Also, the genetics of a cancer tumor is furthering research advancement in individualized drug therapies.  Below are  few screen shots of power points that were being discussed.

Pros and con of radiation therapy...

The way we treated breast cancer in 1882 to
the advancements and discoveries over
the years

The genetic make-up of a breast cancer tumor
is changing the way of research to
discover targeted therapies

Triple Negative Breast Cancer research
in trials for:BRCA positive, PIK3CA mutations
and Immunotherapy

30% of patients with early stage breast cancer
will experience a recurrence within
5 years of diagnosis, but...

Living Beyond Beast Cancer Conference Philadelphia 2018

On September 28, 2018, I attended the Living Beyond Breast Cancer Conference that was co-hosted by The Triple Negative Breast Cancer Foundation in Philadelphia. A lot of  promising research is still ongoing for Triple Negative Breast Cancer... PARP Inhibitors was FDA approved in October 2018 for BRCA positive metastatic TNBC.  Immunotherapy and Antibody-drug conjugates is also emerging in TNBC clinical trials with favorable results in complete response in metastatic Triple Negative Breast Cancer. 


My beautiful hotel room view of
Philadelphia skyline

No One Fights Alone!
TNBC sisters Sara K. and Melissa

Hayley Dinerman, Co-founder and President of
Triple Negative Breast Cancer Foundation
https://tnbcfoundation.org

Diagnosed with Triple Negative Breast Cancer
before the age of 60?

Promising Immunotherapy research
for TNBC still in clinical trials

The safety of Pembrolizumab Monotherapy
has demonstrated as being  favorable as
a first-line therapy with PD-L1 positive
Metastatic Triple Negative Breast Cancer.

Breast Cancer Oncologist, Reshma L. Mahtani
Identifying the different subtypes
of Triple Negative Breast Cancer

PARP Inhibitors as an emerging target for
Metastatic TNBC patients that are also
BRCA positive of the gene mutation

Most breast cancer in African women are
triple negative

Who's at higher risk of Triple Negative
Breast Cancer?

Brain metastases is much higher in advanced
Triple Negative Breast Cancer than
other breast cancer subtypes

Me and the ladies of the TNBC Foundation
Allison Axenrod,  Amy Mustica, Melissa Paskvan,
Arlene Brothers and Hayley Dinerman

Fighting for a TNBC
targeted therapy breakthrough!

Pow!

"Rocky"

Breast cancer sisters 
Terlisa Sheppard and Melissa

#KissThis4MBC

Melissa and Josh Levin of
 lymphedivas.com

TNBC sister, Sara K. showing off
her new sleeve just purchased from
a vendor, 
lymphedivas.com


Cheers! 
Party-crasher of a cancer fundraiser!

Triple Negative Breast Cancer sisters
Addys S. and Melissa

Thursday, March 14, 2019

The Victory Center Over the Edge Rappel Challenge 2018


The 2nd annual Over the Edge for Victory was held on September 7, 2018 at the old Toledo Edison Building, one of downtown's tallest buildings.
Over $155,000 was raised for The Victory Center to provide their free support services and programs to cancer survivors and their caregivers in our local community.  Thank you Toledo and surrounding area for supporting this event and making it successful for us survivors. And a very special thank you to Devorah and Kelsey for rappelling down 16 stories and to those who donated money on their behalf.

Rappelling down the Toledo Edison
Building
breast cancer survivor,
Kelsey Smith on the left

Breast cancer survivor Kelsey Smith
She's got this!

Kelsey Smith
I'm walking on sunshine!

Kelsey Smith
And don't it feel good!

Kelsey Smith
I feel the love, I feel the love,
I feel the love that's really real!

Melissa
Chickens don't rappel, just support!

Devorah on the left
16 stories high!

Devorah on left

Gorgeous view, Devorah?

Devorah personally raised $2391!

Karen, Devorah and Penny
So proud of Devorah!

Total Pageviews



"click image to link"